Relating Improvement in Gastrointestinal (CFAbd‐Score <sup>©</sup> ) and Sinonasal (SNOT) Symptoms During Therapy With Elexacaftor/Tezacaftor/Ivacaftor in CF Patients
The burden of symptoms captured with the CFAbd-Score and the SNOT-20-GAV significantly and markedly decreased after ETI initiation. The modest association between changes in both organ-specific symptom scores supports the previously reported individualized electrophysiological responses observed in nasal-potential and intestinal-current measurements.
Authors
- Franziska Duckstein (ORCID: https://orcid.org/0000-0002-0938-8502)
- Carlos Zagoya (ORCID: https://orcid.org/0000-0002-1822-3750)
- Jochen G. Mainz (ORCID: https://orcid.org/0000-0003-3780-7759)
- Olaf Eickmeier (ORCID: https://orcid.org/0000-0003-2835-9886)
- Anton Barucha
- Louise Polte
- Ingo Philipp Fürchtegott Baumann
- Pauline Sadrieh
- Vivien Greiner
- Suzanne van Dullemen
Institutions
- Goethe University Frankfurt (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- Medizinische Hochschule Brandenburg Theodor Fontane (DE)
- Brandenburg University of Applied Sciences (DE)
- Universitätsklinikum Brandenburg an der Havel (DE)
Publication Details
- Journal
- Pediatric Pulmonology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1002/ppul.71507
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00